Ppm1b Negatively Regulates 3-Bromopyruvate Induced Necroptosis in Breast Cancer Cells
Yiming Sun1, Qiong Pan2, Linyan Ma2
1Department of Pharmacy, The First Affiliated Hospital of Bengbu Medical College, Bengbu, China.
Abstract:
Up to 30% of breast cancer mortality is caused by cancer relapse despite primary clinical treatments due to distant metastases. Further research focusing on breast cancer mechanisms are needed for deeper understanding of disease prognosis. 3-bromopyruvate (3-BP), a glycolysis inhibitor, has been studied as one of the antitumor agents in recent years. In this report, we want to investigate the form of cell death induced by 3-BP and demonstrate the inhibitory effect of 3-BP on breast cancer cell proliferation and its mechanism in vivo and in vitro. We found that 3-BP could inhibit MDA-MB-231 and MCF-7 breast cancer cell proliferation, through energy metabolism inhibition. Further, necroptosis characters in MDA-MB-231 cells after 3-BP treatment were observed, which could be negatively regulated through Ppm1b by dephosphorylation of RIP3. In addition, 3-BP treatment in an MDA-MB-231 cell-transplanted mouse model showed a significant antitumor effect, which correlated with necroptosis-related protein Ppm1b. The findings demonstrate the potential for 3-BP in the treatment of breast cancer, providing impetus for further clinical studies.
Insights
3-bromopyruvate (3-BP) inhibits breast cancer cell growth by blocking energy metabolism. This glycolysis inhibitor triggers necroptosis, a form of programmed cell death, showing potential for breast cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Breast cancer mortality is significantly driven by distant metastases and relapse.
- Understanding breast cancer progression mechanisms is crucial for improving patient prognosis.
- 3-bromopyruvate (3-BP), a glycolysis inhibitor, is being explored for its antitumor properties.
Purpose of the Study:
- To investigate the cell death pathways induced by 3-BP in breast cancer.
- To evaluate the inhibitory effects of 3-BP on breast cancer cell proliferation in vitro and in vivo.
- To elucidate the underlying mechanisms of 3-BP's action, including its effect on energy metabolism and specific cell death pathways.
Main Methods:
- In vitro studies using MDA-MB-231 and MCF-7 breast cancer cell lines.
- Analysis of cell proliferation and energy metabolism.
- Investigation of cell death mechanisms, including necroptosis.
- In vivo studies using an MDA-MB-231 cell-transplanted mouse model.
- Assessment of necroptosis-related protein Ppm1b expression and activity.
Main Results:
- 3-bromopyruvate (3-BP) significantly inhibited proliferation of MDA-MB-231 and MCF-7 breast cancer cells.
- 3-BP induced necroptosis in MDA-MB-231 cells, a process negatively regulated by Ppm1b-mediated dephosphorylation of RIP3.
- In vivo administration of 3-BP demonstrated a significant antitumor effect in a mouse model, correlating with Ppm1b levels.
Conclusions:
- 3-bromopyruvate (3-BP) effectively inhibits breast cancer cell proliferation by targeting energy metabolism.
- Necroptosis is a key cell death mechanism induced by 3-BP in breast cancer cells.
- The findings support the potential of 3-BP as a therapeutic agent for breast cancer, warranting further clinical investigation.
More Related Videos
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
15:53Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
Published on: August 21, 2013
Related Concept Videos
02:23Abnormal Proliferation
01:31The Intrinsic Apoptotic Pathway
01:23Negative Regulator Molecules
01:16Necrosis
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...